

WorldMEN 2006

MARSEILLE, France

7 - 10 september 2006

PRELIMINARY PROGRAM



French Study Group of Endocrine Tumors (GTE)

Local Organizing Committee

P. NICCOLI-SIRE, B. CONTE-DEVOLX

International Organizing Committee

A. Beckers (Belgium), J. Bertherat (France), M. L. Brandi (Italy),
W. Farrel (UK), R. Gagel (USA), S. Marx (USA),
F. Raue (Germany), B. Robinson (Australia),
C. Stratakis (USA), R. Thakker (UK),
B. Wiedenmann (Germany), H. Dralle (Germany),
B. Niederle (Austria).





PRELIMINARY SCIENTIFIC PROGRAM

NATURAL HISTORY AND SIGNALING PATHWAYS IN ONCOGENESIS OF ENDOCRINE TUMORS

- Development of C cell disease in familial MTC
- MAP kinase dysregulation in endocrine tumors
- Calcium sensing receptor mutations in hereditary primary hyperparathyroidism
- RET MEN2A targeting in oncogenesis
- RET in cell signalling and apoptosis
- Krebs cycle, angiogenesis and oncogenesis in SDH related tumors
- Functions of genes in VHL disease
- Tumor suppressing function of MEN1

Animal models of endocrine tumors

- Lessons on endocrine tumorigenesis from mice model of MEN1
- Lessons on endocrine tumorigenesis from mice : models of Carney complex C
- SDHD animal models

GENETIC TOPICS/ PHENOTYPE-GENOTYPE RELATIONSHIPS

- Pheochromocytoma/Paraganglioma syndromes : genotype-phenotype associations
- Phenotype-genotype correlations in familial medullary thyroid carcinoma with non cysteine RET mutations
- Polymorphisms of the RET gene
- Genotype-phenotype correlations in VHL disease
- Genotype-phenotype correlations in Carney disease
- Germline mutations in MEN1 syndrome and related clinical features.

CURRENT DIAGNOSTIC PROCEDURES IN ENDOCRINE TUMORS

- Endoscopic ultrasound in detecting gastro-enteropancreatic tumors
- Pet scan and diagnosis of endocrine tumors
- Radionuclear imaging, somatostatin analogs scintigraphy
- Conventional imaging of endocrine tumors and risk of induced carcinogenesis



MEDICAL TREATMENTS IN ENDOCRINE TUMORS / PRESENT AND FUTURE

- SST subtypes in MTC
- Somatostatin receptor scintigraphy and somatostatin analog-coupled isotopes for therapy
- Tyrosine kinase inhibitors
- Other genetic potential future therapies in MTC
- Calcimimetic therapy in primary hyperparathyroidism
- Rationale of anti-angiogenic therapy in endocrine tumors

SURGICAL MANAGEMENT OF HEREDITARY ENDOCRINE TUMORS

- Management of gastro-enteropancreatic tumors in MEN1
- Lymph node surgery in sporadic and familial MTC
- Cortical sparing surgery in the management of endocrine tumors
- Thymectomy in children
- Pancreatic surgery in children
- Surgical options in HPTR2 positive parathyroid cancer

DIAGNOSIS AND MANAGEMENT OF GENETICALLY AT RISK SUBJECTS OF HEREDITARY ENDOCRINE TUMORS

- Ethical, psychological, and legal aspects of genetic testing in familial endocrine tumors prenatal and preimplantary diagnosis
- Management of MEN1 at risk patients
- Management of patients at risk of hereditary paraganglioma
- Management of genetically affected patients with VHL disease

PROGNOSIS FACTORS IN ENDOCRINE TUMORS

- Prognostic factors in metastatic GEP tumors
- Differences in sporadic and MEN1 pancreatic endocrine tumor pathology





Venue : Palais du Pharo, Marseille, France.

Contact Person : P. NICCOLI-SIRE
address : Service Endocrinologie,
CHU Timone, 254 rue St Pierre,
13385 Marseille, Cedex 05 France
Phone : + 33 4 91 38 65 97
Fax : + 33 4 91 38 45 42
e-mail : patricia.niccoli-sire@ap-hm.fr

congress website :
www.endocrino.net/GTE

